Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
373 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01361607 | Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer(SPRAY III) | completed | Phase 3 | 399 | Jazz PharmaceuticalsINDUSTRY | 10 | Apr 12, 2023 | clinicaltrials |
| NCT01424566 | A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer | completed | Phase 3 | 406 | Jazz PharmaceuticalsINDUSTRY | 13 | Apr 12, 2023 | clinicaltrials |
| NCT01126190 | Neugranin in Breast Cancer Participants Receiving Doxorubicin/Docetaxel(NEUGR-003) | completed | Phase 3 | 381 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 5 | Mar 28, 2023 | clinicaltrials |
| NCT02172872 | "InDACtion" vs "3+7" Induction in AML | unknown | Phase 3 | 606 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Feb 15, 2023 | clinicaltrials |
| NCT03286842 | To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients. | completed | Phase 3 | 256 | AstraZenecaINDUSTRY | 15 | Jan 17, 2023 | clinicaltrials |
| NCT02703272 | A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma | terminated | Phase 3 | 72 | Janssen Research & Development, LLCINDUSTRY | 20 | Dec 2, 2022 | clinicaltrials |
| NCT00858364 | Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy | terminated | Phase 3 | 2,549 | AmgenINDUSTRY | 37 | Nov 30, 2022 | clinicaltrials |
| NCT01568866 | Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients(ENDEAVOR) | completed | Phase 3 | 929 | AmgenINDUSTRY | 27 | Nov 14, 2022 | clinicaltrials |
| NCT01345019 | Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma | completed | Phase 3 | 1,718 | AmgenINDUSTRY | 29 | Nov 8, 2022 | clinicaltrials |
| NCT01001377 | ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer | completed | Phase 3 | 1,010 | AmgenINDUSTRY | 29 | Sep 21, 2022 | clinicaltrials |
| NCT01080391 | Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma | completed | Phase 3 | 792 | AmgenINDUSTRY | 20 | Sep 21, 2022 | clinicaltrials |
| NCT02747043 | Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab(JASMINE) | completed | Phase 3 | 256 | AmgenINDUSTRY | 20 | Sep 10, 2022 | clinicaltrials |
| NCT00625378 | Sorafenib Long Term Extension Program(STEP) | completed | Phase 3 | 206 | BayerINDUSTRY | 19 | Sep 1, 2022 | clinicaltrials |
| NCT00966914 | Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin | completed | Phase 3 | 540 | BioNumerik Pharmaceuticals, Inc.INDUSTRY | 6 | Jul 13, 2022 | clinicaltrials |
| NCT02340221 | A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy(SANDPIPER) | terminated | Phase 3 | 631 | Hoffmann-La RocheINDUSTRY | 28 | Jul 12, 2022 | clinicaltrials |
| NCT02200614 | Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer(ARAMIS) | completed | Phase 3 | 1,509 | BayerINDUSTRY | 36 | Jun 28, 2022 | clinicaltrials |
| NCT00920816 | Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer | completed | Phase 3 | 492 | PfizerINDUSTRY | 14 | May 6, 2022 | clinicaltrials |
| NCT01095003 | Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer | completed | Phase 3 | 770 | Pierre Fabre MedicamentINDUSTRY | 21 | Apr 28, 2022 | clinicaltrials |
| NCT01702571 | A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment | completed | Phase 3 | 2,185 | Hoffmann-La RocheINDUSTRY | 43 | Apr 4, 2022 | clinicaltrials |
| NCT04633564 | MYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLC | completed | Phase 3 | 671 | Mylan Pharmaceuticals IncINDUSTRY | 17 | Mar 16, 2022 | clinicaltrials |
| NCT02810457 | Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer(AVANA) | completed | Phase 3 | 731 | Centus Biotherapeutics LimitedINDUSTRY | 24 | Mar 10, 2022 | clinicaltrials |
| NCT02467868 | Efficacy and Safety Study With MYL-1401H and Neulasta | completed | Phase 3 | 193 | Mylan Inc.INDUSTRY | 6 | Feb 14, 2022 | clinicaltrials |
| NCT02566993 | Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer(ATLANTIS) | completed | Phase 3 | 613 | PharmaMarINDUSTRY | 20 | Oct 28, 2021 | clinicaltrials |
| NCT01077154 | Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE) | terminated | Phase 3 | 4,509 | AmgenINDUSTRY | 39 | Sep 28, 2021 | clinicaltrials |
| NCT02366143 | A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)(IMpower150) | completed | Phase 3 | 1,202 | Hoffmann-La RocheINDUSTRY | 26 | Sep 23, 2021 | clinicaltrials |
| NCT01363479 | An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting | completed | Phase 3 | 743 | Helsinn Healthcare SAINDUSTRY | 12 | Sep 22, 2021 | clinicaltrials |
| NCT03033511 | A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)(MERU) | terminated | Phase 3 | 748 | AbbVieINDUSTRY | 41 | Jul 29, 2021 | clinicaltrials |
| NCT02163759 | A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors(HIBISCUS I) | completed | Phase 3 | 358 | Hoffmann-La RocheINDUSTRY | 14 | Jul 23, 2021 | clinicaltrials |
| NCT02171429 | A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors(HIBISCUS II) | completed | Phase 3 | 358 | Hoffmann-La RocheINDUSTRY | 19 | Jul 23, 2021 | clinicaltrials |
| NCT01743989 | A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.(ENESTPath) | completed | Phase 3 | 620 | Novartis PharmaceuticalsINDUSTRY | 21 | Jul 15, 2021 | clinicaltrials |
| NCT01964378 | CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to Cancer(CORAL) | terminated | Phase 3 | 200 | Tris Pharma, Inc.INDUSTRY | 14 | Jul 15, 2021 | clinicaltrials |
| NCT02031432 | CORAL XT - Open-label Extension Trial of the CORAL Trial(CORAL XT) | completed | Phase 3 | 76 | Tris Pharma, Inc.INDUSTRY | 10 | Jul 15, 2021 | clinicaltrials |
| NCT00878709 | Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer(ExteNET) | completed | Phase 3 | 2,840 | Puma Biotechnology, Inc.INDUSTRY | 40 | Jun 11, 2021 | clinicaltrials |
| NCT02218047 | AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.(CONTI-PV) | completed | Phase 3 | 170 | AOP Orphan Pharmaceuticals AGINDUSTRY | 12 | Jun 1, 2021 | clinicaltrials |
| NCT01100502 | A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial) | completed | Phase 3 | 329 | Seagen Inc.INDUSTRY | 13 | May 14, 2021 | clinicaltrials |
| NCT01419665 | GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)(ASSIST_FL) | completed | Phase 3 | 629 | SandozINDUSTRY | 26 | May 14, 2021 | clinicaltrials |
| NCT01566721 | A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer(SafeHER) | completed | Phase 3 | 2,577 | Hoffmann-La RocheINDUSTRY | 59 | Apr 27, 2021 | clinicaltrials |
| NCT03296163 | A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)(STELLA) | completed | Phase 3 | 627 | mAbxience Research S.L.INDUSTRY | 18 | Apr 26, 2021 | clinicaltrials |
| NCT02111577 | Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer(VIABLE) | completed | Phase 3 | 1,182 | SOTIO a.s.INDUSTRY | 22 | Apr 6, 2021 | clinicaltrials |
| NCT00796445 | A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor | terminated | Phase 3 | 1,351 | GlaxoSmithKlineINDUSTRY | 32 | Mar 5, 2021 | clinicaltrials |
| NCT03070951 | Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids(PRIMROSE 2) | completed | Phase 3 | 511 | ObsEva SAINDUSTRY | 9 | Mar 5, 2021 | clinicaltrials |
| NCT03520478 | A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer | unknown | Phase 3 | 654 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 4 | Mar 2, 2021 | clinicaltrials |
| NCT00073528 | Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer | completed | Phase 3 | 1,286 | Novartis PharmaceuticalsINDUSTRY | 29 | Feb 24, 2021 | clinicaltrials |
| NCT02369874 | Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer(EAGLE) | completed | Phase 3 | 736 | AstraZenecaINDUSTRY | 24 | Feb 10, 2021 | clinicaltrials |
| NCT01774786 | A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer(JACOB) | completed | Phase 3 | 780 | Hoffmann-La RocheINDUSTRY | 32 | Dec 30, 2020 | clinicaltrials |
| NCT03098030 | Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 483 | United TherapeuticsINDUSTRY | 23 | Dec 9, 2020 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials